<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395978</url>
  </required_header>
  <id_info>
    <org_study_id>Phase II BLI-1005-002</org_study_id>
    <nct_id>NCT02395978</nct_id>
  </id_info>
  <brief_title>A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioLite, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioLite, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy in patients with major
      depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary endpoint is the change of Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline to Week 6 compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2 and 7 weeks</time_frame>
    <description>MADRS total score－change from baseline to Visit 2 and 6 (Week 2 and 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D-17)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Change from baseline to Visit 3, 4, 5 and 6 (Week 2, 4, 6 and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Change from baseline to Visit 3, 4, 5 and 6 (Week 2, 4, 6 and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression and Somatic Symptoms Scale (DSSS)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Change from baseline to Visit 3, 4, 5 and 6 (Week 2, 4, 6 and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale (CGI)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Change from baseline to Visit 3, 4, 5 and 6 (Week 2, 4, 6 and 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Percentage of partial responders (defined as a participant with a 25-50% decrease from baseline in total score) and responders (defined as a participant with ≧50% decrease from baseline in total score) in MADRS by week 2, 4, 6 and 7 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments and Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Evaluate Safety Assessments and Columbia-Suicide Severity Rating Scale (C-SSRS) from screening stage to week 2, 4, and 5.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>2 PDC-1421 Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 PDC-1421 Capsule TID, p.o. after meal for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo TID, p.o. after meal for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDC-1421 Capsule</intervention_name>
    <arm_group_label>2 PDC-1421 Capsule</arm_group_label>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>1 PDC-1421 Capsule plus 1 placebo</arm_group_label>
    <arm_group_label>2 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients aged 20-65 years

          2. Subjects must be able to understand and willing to sign informed consent

          3. Female subjects of child-bearing potential must test negative to pregnancy and use
             appropriate birth control method from the beginning of study to the 15 days later
             after ending of study

          4. Met criteria for MDD without psychotic features as defined by the Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition Text Revision® (DSM-IV-TR) and
             confirmed by use of the Mini International Neuropsychiatric Interview (MINI).

          5. 17-item HAM-D (Hamilton Rating Scale for Depression) total score ≧20 and CGI (Clinical
             Global Impression) total score ≧4

        Exclusion Criteria:

          1. Have a current or previous major psychiatric disorders which be defined to be per the
             DSM-IV-TR, including obsessive-compulsive disorder, posttraumatic stress disorder,
             bipolar I or II, manic or hypomanic episode, schizophrenia, major Axis II disorders
             which might compromise the study, and major depression with psychotic symptoms, mental
             retardation.

          2. Use of any treatment for MDD in the last 2 weeks before visit 1 (4 weeks for
             fluoxetine).

          3. Use of psychoactive drugs within the last 2 weeks before visit 1 other than that
             subjects had insomnia who need the treatment as determined by the Investigator.

          4. Subjects who were non-responsive to two or more courses of antidepressant medications
             given an adequate dosage for symptom treatment within four weeks, or by the judgment
             of the investigator considered to have treatment resistant depression (TRD), or a
             history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or
             psychosurgery within the last year.

          5. Have a history of any seizure disorder.

          6. Any clinically significant abnormal vital sign, ECG, laboratory values as determined
             by the investigator which might interfere with the study.

          7. Any organic disorder caused u medical related depression which cannot be under
             well-controlled such as clinically significant in neurological, gastrointestinal,
             renal, hepatic, cardiovascular, respiratory, metabolic, endocrine, hematological or
             other major disorders

          8. Have a high suicidal risk as measured by MINI.

          9. Have a history of substance abuse within the past 6 months or a positive urine drug
             screen for any substance of abuse at visit 1.

         10. Have a history of severe allergies to more than 1 class of medication or multiple
             adverse drug reactions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Po Chen, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychosomatic Medicine, Taipei City Psychiatric Center, Taipei City Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank Chang, PhD</last_name>
    <phone>886-3-657-9631</phone>
    <phone_ext>13</phone_ext>
    <email>frankchang@bioliteinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford Depression Research Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles DeBattista, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei City Hospital, Songde Branch</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kun-Po Po, M.D., M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cheng-Ta Li, M.D.,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital, Neihu Main Facility</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei-Chung Mao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wan Fang Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mong-Liang Lu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chia- Yih Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

